Established in 1997, under the philosophy of “making good medicines for China and repaying the world with good deeds”, Shiyi Pharmaceutical Holding Group Co., Ltd. has maintained double-digit growth in its main business indexes for many years through innovative development. Now it has developed into an internationalized innovative enterprise with 28,000 employees. Its Hong Kong-listed company was selected as a constituent stock of the Hang Seng Index, and on behalf of China Pharmaceutical, it was ranked 24th on the list of global pharmaceutical companies in terms of R&D pipeline size, serving patients all over the world.

Together, we are leading the way to life and health through science. We have a broad portfolio of scientific products, advanced drug discovery and manufacturing capabilities, and a fully integrated platform of CDMO and contract testing services for both traditional and novel pharmaceuticals. We are committed to creating a sustainable future for the next generation with innovative products, high-quality services and digital solutions for the benefit of the world.

WuXi AppTec provides integrated, end-to-end drug discovery and manufacturing services to the global pharmaceutical and life sciences industries, with operations in Asia, Europe and North America. Through its unique “CRDMO” and “CTDMO” business models, WuXi AppTec continuously lowers the threshold of R&D, helps clients improve R&D efficiency, and brings more breakthrough therapeutic solutions to patients, with services ranging from chemical R&D and manufacturing, biological research, preclinical testing and clinical trial R&D, precision medicine, and biotechnology, biological research, preclinical testing and clinical trial R&D, precision medicine R&D, testing and manufacturing, etc. In 2023, WuXi PharmaTech was rated AA in ESG (Environmental, Social and Governance) by MSCI for the third consecutive year. Currently, the company's empowerment platform is carrying the R&D and innovation projects of more than 6,000 partners from more than 30 countries around the world, and is committed to bringing more new and better medicines to patients around the globe and realizing the vision of “making the world free of hard-to-make medicines and hard-to-treat diseases” as soon as possible.